Author:
Uzun Ozsahin Dilber,Sheshakli Sameer,Kibarer Ayse Gunay,Denker Ali,Duwa Basil Bartholomew
Reference23 articles.
1. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance;Pettitt;Nat. Communicat.,2018
2. P. Goss, J. Ingle, S. Martino, et al., Updated analysis of the NCIC CTC MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proceedings from the 40th Annual Meeting of the American Society of Clinical Oncology Best of Oncology Symposium, New Orleans, LA, 2004 (Abstract #847).
3. Older women with localized breast cancer: costs and survival rates increased across two time periods;Feinstein;Health Affairs,2015
4. Effectiveness of postoperative physical therapy for upper-limb impairments after breast cancer treatment: a systematic review;De Groef;Arch. Phys. Med. Rehab.,2015
5. 2006 highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA, June 2006;Muneer;Clin. Breast Canc.,2006
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献